The Efficacy of Selective Laser Trabeculoplasty

Sponsor
Glaucoma Research & Education Group (Other)
Overall Status
Unknown status
CT.gov ID
NCT00347893
Collaborator
PharmaLogic Development, Inc. (Industry)
1

Study Details

Study Description

Brief Summary

Selective laser trabeculoplasty (SLT) is a new method to reduce intraocular pressure in eyes with open angle glaucoma or ocular hypertension. SLT may also be effective for cases with previously failed ALT procedures. We will study the efficacy and safety of the SLT procedure.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Selective laser trabeculoplasty

Detailed Description

Selective laser trabeculoplasty (SLT) has been shown to be a safe, well tolerated, and effective intraocular pressure reduction therapy for several forms of open-angle glaucoma. SLT produces significantly less disturbance to the trabecular meshwork and is theoretically more repeatable than the ALT procedure. This retrospective research will begin with cases treated in 2001. It will evaluate whether SLT is effective for patients who have had prior treatment with ALT and it will determine whether the IOP lowering effect is sustainable over time. It will also assess the efficacy of repeated SLT procedures.

Study Design

Study Type:
Observational
Observational Model:
Defined Population
Time Perspective:
Retrospective
Official Title:
Clinical Results of Selective Laser Trabeculoplasty in Treatment of Open Angle Glaucoma
Study Start Date :
May 1, 2006

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    0 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patients with primary open angle glaucoma, ocular hypertension, pseudo exfoliative glaucoma, pigment dispersion glaucoma
    Exclusion Criteria:
    • History of prior invasive glaucoma surgery

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Glaucoma Center of San Francisco San Francisco California United States 94105

    Sponsors and Collaborators

    • Glaucoma Research & Education Group
    • PharmaLogic Development, Inc.

    Investigators

    • Principal Investigator: Andrew G. Iwach, M.D., Glaucoma Research & Education Group

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00347893
    Other Study ID Numbers:
    • 22222
    First Posted:
    Jul 4, 2006
    Last Update Posted:
    Jul 4, 2006
    Last Verified:
    Jun 1, 2006

    Study Results

    No Results Posted as of Jul 4, 2006